Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Darifenacin (DAR328), Enablex
Darifenacin · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Darifenacin |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Darifenacin | DRUG | Darifenacin 15 mg tablets once daily |
| Placebo | DRUG | Placebo tablets once daily |
Inclusion Criteria: * Three symptoms of OAB (urge incontinence, frequency and urgency) for at least six months prior to Visit 2. * Patients capable of independent toileting and able of independently completing the patient diary. Exclusion Criteria: * Patients in whom the use of anticholinergic dr...
Darifenacin is used for overactive bladder syndrome, a urology condition. It is a small molecule developed by Novartis AG under the ticker NVS. The clinical program includes two completed Phase 3 trials in adults with overactive bladder, one evaluating warning time and one assessing long-term safety, tolerability and efficacy.
Darifenacin targets CHRM3 and CHRM2, which are muscarinic acetylcholine receptors. It acts as an antagonist at these receptors. By blocking these targets, darifenacin is designed to reduce bladder contractions associated with overactive bladder syndrome. The compound is a small molecule and is identified in ChEMBL as CHEMBL1346.
Darifenacin is developed by Novartis AG, which trades under the ticker NVS. Novartis is the company behind the clinical development program for darifenacin in overactive bladder syndrome. The asset is also referred to as darifenacin (DAR328) in development records.
Darifenacin is in Phase 3 development for overactive bladder syndrome. Two Phase 3 trials have been completed, and no trials are currently active. The program has enrolled 1,163 patients in total across randomized, double-blind, placebo-controlled studies in adults aged 18 years and older.
Darifenacin has been studied in two completed Phase 3 trials. NCT00171145 was a 12-week study evaluating darifenacin to increase warning time in patients with overactive bladder, enrolling 445 participants. NCT00170755 was a long-term safety, tolerability and efficacy study in adult patients with overactive bladder, enrolling 718 participants. Both were conducted in the United States.
Yes, DAR328 is an alternative name for darifenacin. The two names refer to the same small molecule developed by Novartis AG for overactive bladder syndrome. Readers searching for DAR328 will find the same Phase 3 asset, which targets CHRM3 and CHRM2 as an antagonist.